7 completed, 6 terminated, 5 recruiting, 4 unknown. 15 Phase 2, 4 Phase 1, 3 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Non-small Cell Lung Cancer Stage IV: new trials by email Literature Review of Non-small Cell Lung Cancer Stage IV trials Research Report on Non-small Cell Lung Cancer Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept - Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 26 | 2026-07-07 | 2026-07-10 |
| Pulmonary Rehabilitation in Advanced Lung Cancer Survivors Pulmonary Rehabilitation (PR), No intervention: Usual care - Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 85 | 2026-03-16 | 2026-09-22 |
| Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care - Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV | Phase 2 | Recruiting | University of California, Davis | 56 | 2026-01-30 | 2026-08-25 |
| [177Lu]Lu-AKIR001 First-in-human Study [177Lu]Lu-AKIR001 - Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma | Early Phase 1 | Recruiting | Karolinska University Hospital | 15 | 2026-01-28 | 2026-01-30 |
| Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial Xingbaiji Formula - Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent | Not applicable | Not yet recruiting | Jiangxi Provincial People's Hopital | 100 | 2025-03-10 | 2025-02-27 |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC - Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma | Phase 2 | Recruiting | Genelux Corporation | 142 | 2024-09-26 | 2026-06-04 |
| Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC Osimertinib - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 93 | 2024-06-01 | 2024-05-30 |
| A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer SB27, Keytruda - Non-small Cell Lung Cancer Stage IV | Phase 3 | Active not recruiting | Samsung Bioepis Co., Ltd. | 555 | 2024-03-12 | 2026-10-26 |
| The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC Furmonertinib - Non Small Cell Lung Cancer, EGFR Gene Mutation | Unknown | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 30 | 2023-11-01 | 2023-11-07 | |
| Intrathecal Double Checkpoint Inhibition intrathecal nivolumab and intrathecal ipilimumab - Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV | Phase 1 | Active not recruiting | University of Zurich | 26 | 2022-11-25 | 2025-10-02 |
| Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet) DigiNet intervention - Non-small Cell Lung Cancer Stage IV | Not applicable | Unknown | University of Cologne | 850 | 2022-06-01 | 2024-06-04 |
| Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC Envafolimab - Non-small Cell Lung Cancer Stage IV | Phase 2 | Unknown | The First Affiliated Hospital of Xiamen University | 20 | 2021-08-30 | 2021-09-24 |
| A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3 - Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB | Phase 1 | Terminated | Imugene Limited | 24 | 2020-11-30 | 2026-03-25 |
| Immunotherapy in Patient With Poor General Condition Durvalumab - Non-small Cell Lung Cancer Stage IV | Phase 2 | Completed | Intergroupe Francophone de Cancerologie Thoracique | 50 | 2020-10-14 | 2025-10-03 |
| Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) Aspirin, Osimertinib - Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Unknown | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 100 | 2020-08-01 | 2020-07-23 | |
| Tumor Mutational Burden in Lung Cancer Patients TMB assessment - Non Small Cell Lung Cancer, Non-Small Cell Carcinoma of Lung | Terminated | Assistance Publique - Hôpitaux de Paris | 6 | 2020-06-10 | 2021-06-24 | |
| Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis Atezolizumab - Non-small Cell Lung Cancer Stage IV | Phase 2 | Completed | Spanish Lung Cancer Group | 40 | 2018-07-07 | 2024-10-09 |
| Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy - Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV | Phase 1 | Terminated | University of Wisconsin, Madison | 17 | 2018-02-20 | 2023-05-15 |
| Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC Osimertinib, Aspirin - Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 2 | Completed | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 115 | 2018-01-01 | 2025-02-27 |
| A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Abemaciclib, Docetaxel - Non-Small Cell Lung Cancer Stage IV | Phase 2 | Completed | Eli Lilly and Company | 159 | 2015-08-06 | 2021-08-13 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (26) · Lung Neoplasms (5) · Carcinoma (2) · Adenocarcinoma of Lung (1) · Disease (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Meningeal Carcinomatosis (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Thyroid Carcinoma, Anaplastic (1) · Uterine Cervical Neoplasms (1) · Vaccinia (1) · Vulvar Neoplasms (1)
Bronchial Neoplasms (26) · Carcinoma, Bronchogenic (26) · Lung Diseases (26) · Respiratory Tract Diseases (26) · Respiratory Tract Neoplasms (26) · Thoracic Neoplasms (26) · Neoplasms (25) · Neoplasms by Site (25) · Lung Neoplasms (21) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (2) · Adenocarcinoma (1) · Central Nervous System Neoplasms (1) · DNA Virus Infections (1)
Docetaxel (5) · atezolizumab (3) · durvalumab (3) · osimertinib (3) · Aspirin (2) · Cisplatin (2) · Nivolumab (2) · 130-nm albumin-bound paclitaxel (1) · ALT-803 (1) · Bevacizumab (1) · Carboplatin (1) · Gemcitabine (1) · Ipilimumab (1) · Pemetrexed (1) · Radiosurgery (1)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (4) · Synta Pharmaceuticals Corp. (2) · Assistance Publique - Hôpitaux de Paris (1) · Case Comprehensive Cancer Center (1) · Eli Lilly and Company (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Genelux Corporation (1) · Golden Biotechnology Corporation (1) · Imugene Limited (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Jiangxi Provincial People's Hopital (1) · Karolinska University Hospital (1) · Pharmatech (1) · Samsung Bioepis Co., Ltd. (1) · Sanofi (1)
United States (10) · Germany (6) · Spain (6) · France (5) · Italy (4) · Romania (4) · Bosnia and Herzegovina (3) · China (3) · Poland (3) · Russia (3) · Serbia (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Canada (2)
Alessandro Bertolini, MD (1) · Alessandro Del Conte, MD (1) · Andrea De Monte (1) · Anna Paola Fraccon, MD (1) · Antonio Febbraro, MD (1) · Antonio Pazzola, MD (1) · Benjamin Besse, MD (1) · Chandra P Belani, MD (1) · Daniele Pozzessere, MD (1) · Ernest Nadal, MD (1) · Etienne Rouleau, PharmD, PhD (1) · Fabrizio Nelli, MD (1) · Francesco Verderame, MD (1)
PMID 27959700, PMID 25139550, PMID 37603816, PMID 40924208, PMID 41121745, PMID 41198237
2009 (1), 2014 (1), 2017 (1), 2023 (1)